Rhythm Pharmaceuticals Inc Dossier - Source-backed chat

Rhythm Pharmaceuticals Inc

RYTMNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.65

Intrinsic Value $103.64median of 2 methodsbased on filings through 30 Jun 2026

Market Price $93.41Price as of 1 Oct 2026

Near fair valueIntrinsic value is 11% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $6.4B

Enterprise Value $6.5B

Shares Outstanding 69.9M diluted

Next Earnings Date5 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Rhythm Pharmaceuticals is transitioning into a high-growth, commercial-stage rare disease powerhouse. The investment thesis is anchored on the rapid commercial adoption of its precision melanocortin-4 receptor (MC4R) agonist, IMCIVREE (setmelanotide), particularly following its March 2026 FDA approval for acquired hypothalamic obesity (HO). With strong international sales momentum, positive Phase 2 data in Prader-Willi Syndrome (PWS) de-risking the pipeline, and a robust cash position of $340.6 million, Rhythm is well-positioned to capture a multi-billion dollar rare neuroendocrine market.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets15 analysts · as of 18 Aug 2026

Low · most bearish analyst$105.00

Mean target$141.53

High · most bullish analyst$160.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$105.0020%

Commercial uptake of IMCIVREE in acquired HO slows due to reimbursement hurdles or high patient discontinuation rates. Pipeline candidates face clinical or regulatory delays, and the cash burn rate accelerates, forcing dilutive capital raises before the company reaches profitability.

Base CaseCentral scenario

$141.5350%

Matches the consensus mean

IMCIVREE maintains steady commercial growth in Bardet-Biedl Syndrome (BBS) and acquired HO, supported by expanding payer coverage and international reimbursement. The company successfully initiates the Phase 3 PWS trial and achieves Japanese approval by late 2026. Operating expenses remain within the guided $385M-$415M range, and corporate profitability is achieved by 2028.

Bull CaseUpside scenario

$155.0030%

The launch of IMCIVREE in acquired hypothalamic obesity exceeds expectations, capturing a significant portion of the estimated 10,000-patient addressable market in the U.S. and Europe. Concurrently, the Phase 3 trial in Prader-Willi Syndrome (PWS) delivers outstanding topline results, and Japanese PMDA approval is secured ahead of schedule in late 2026, driving peak sales projections toward $2 billion by 2030.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

First-mover advantage and dominant market share (>90%) in specialized MC4R pathway pharmacotherapy.
Highly successful launch in acquired hypothalamic obesity with over 150 start forms in the first six weeks post-approval.
Strong international commercial execution, with international sales growing 27% sequentially in Q1 2026.
De-risked pipeline supported by positive Phase 2 data in Prader-Willi Syndrome showing clinically meaningful BMI and hyperphagia reductions.

Key Investment Risks

High concentration risk with near-term valuation heavily tied to a single commercial asset (IMCIVREE).
Substantial cash burn typical of commercial-stage biotechs, with profitability not expected until 2028.
Potential long-term competition in the rare genetic obesity space and complex reimbursement landscapes globally.

Thesis Invalidation Triggers

Failure to obtain PMDA marketing approval in Japan by the end of 2026.
A significant safety signal emerging from the long-term use of setmelanotide.
Clinical trial failure or failure to align with regulators on the Phase 3 trial design for Prader-Willi Syndrome.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.